keyword
MENU ▼
Read by QxMD icon Read
search

Statins CKD

keyword
https://www.readbyqxmd.com/read/29423043/greater-low-density-lipoprotein-cholesterol-variability-is-associated-with-increased-progression-to-dialysis-in-patients-with-chronic-kidney-disease-stage-3
#1
Yu-Hsuan Lin, Jiun-Chi Huang, Pei-Yu Wu, Szu-Chia Chen, Yi-Wen Chiu, Jer-Ming Chang, Hung-Chun Chen
Increasing evidence suggests that lipid variability may be a predictor of cardiovascular events. However, few studies have evaluated the association between lipid variability and renal outcomes in patients with moderate-to-advanced chronic kidney disease (CKD). Therefore, the aims of this study were to assess whether lipid variability is associated with progression to dialysis in patients with CKD stage 3-5, and to evaluate the risk factors of lipid variability. This longitudinal study enrolled 725 patients with CKD stage 3-5...
January 9, 2018: Oncotarget
https://www.readbyqxmd.com/read/29378035/skin-autofluorescence-arterial-stiffness-and-framingham-risk-score-as-predictors-of-clinical-outcome-in-chronic-kidney-disease-patients-a-cohort-study
#2
Hideyuki Mukai, Oskar Svedberg, Bengt Lindholm, Lu Dai, Olof Heimbürger, Peter Barany, Björn Anderstam, Peter Stenvinkel, Abdul Rashid Qureshi
Background: The risk of cardiovascular disease (CVD) is predicted by Framingham's CVD risk scores (FRS) but the high CVD-related mortality in patients with chronic kidney disease (CKD) is only partially explained by traditional CVD risk markers. Therefore, there is a need to explore whether other CVD risk markers may improve risk prediction. Although arterial stiffness measured by augmentation index (AIx) and tissue content of advanced glycation end-products (AGEs) measured by skin autofluorescence (SAF) are two biomarkers that associate with CVD and mortality in CKD, it is not known how they compare with FRS...
January 25, 2018: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29318962/is-statin-therapy-safe-and-effective-in-patients-with-chronic-kidney-disease
#3
Venkatesh K Raman, Eleni Geladari, Vasilios Papademetriou
Chronic kidney disease (CKD) is associated with dyslipidemia and increased cardiovascular risk. This elevated risk for cardiovascular events exists even in the largest subpopulation with milder stages of CKD, prior to the development of significant reductions in renal excretory function. Statin therapy is a critical component of primary and secondary cardiovascular prevention efforts for at-risk patients. Efficacy in the CKD population, however, has appeared less robust across the spectrum of CKD, particularly in hemodialysis patients...
January 9, 2018: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29299849/lipid-management-in-chronic-kidney-disease-systematic-review-of-pcsk9-targeting
#4
REVIEW
BinBin Zheng-Lin, Alberto Ortiz
Cardiovascular disease is the leading cause of death in patients with chronic kidney disease (CKD) and CKD is considered a coronary artery disease risk equivalent. So far, statins have been the mainstay of primary and secondary prevention of cardiovascular disease in the general population. However, their benefit on outcomes is limited and controversial in CKD patients and new therapeutic approaches to reduce cardiovascular risk are needed. Monoclonal antibodies targeting proprotein convertase subtilisin/kexin 9 (PCSK9) reduce low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) in high-risk populations and cardiovascular events in secondary prevention...
January 3, 2018: Drugs
https://www.readbyqxmd.com/read/29191193/adequacy-of-control-of-cardiovascular-risk-factors-in-ambulatory-patients-with-type-2-diabetes-attending-diabetes-out-patients-clinic-at-a-county-hospital-kenya
#5
Mercy W Kimando, Frederick C F Otieno, Elijah N Ogola, Kenn Mutai
BACKGROUND: Type 2 diabetes is associated with substantial cardiovascular morbidity and mortality arising from the high prevalence of cardiovascular risk factors such as hypertension, dyslipidaemia, obesity, poor glycaemic control and albuminuria. Adequacy of control of these risk factors determines the frequency and outcome of cardiovascular events in the patients. Current clinical practice guidelines emphasize primary prevention of cardiovascular disease in type 2 diabetes. There is scarce data from the developing countries, Kenya included, on clinical care of patients with type 2 diabetes in the regions that are far away from tertiary health facilities...
December 1, 2017: BMC Endocrine Disorders
https://www.readbyqxmd.com/read/29137111/effect-of-omega-3-fatty-acid-supplementation-on-plasma-fibroblast-growth-factor-23-levels-in-post-myocardial-infarction-patients-with-chronic-kidney-disease-the-alpha-omega-trial
#6
Martin H de Borst, Leandro C Baia, Ellen K Hoogeveen, Erik J Giltay, Gerjan Navis, Stephan J L Bakker, Johanna M Geleijnse, Daan Kromhout, Sabita S Soedamah-Muthu
Fibroblast growth factor 23 (FGF23) is an independent risk factor for cardiovascular mortality in chronic kidney disease. Omega-3 (n-3) fatty acid consumption has been inversely associated with FGF23 levels and with cardiovascular risk. We examined the effect of marine n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and plant-derived alpha-linolenic acid (ALA) on plasma FGF23 levels in post-myocardial infarction patients with chronic kidney disease. In the randomized double-blind Alpha Omega Trial, 4837 patients with a history of myocardial infarction aged 60-80 years (81% men) were randomized to one of four trial margarines supplemented with a targeted additional intake of 400 mg/day EPA and DHA, 2 g/day ALA, EPA-DHA plus ALA, or placebo for 41 months...
November 11, 2017: Nutrients
https://www.readbyqxmd.com/read/29110930/determinants-of-acute-kidney-injury-and-renal-function-decline-after-endovascular-abdominal-aortic-aneurysm-repair
#7
Randolph G Statius van Eps, Banne Nemeth, Ronne T A Mairuhu, Jan J Wever, Hugo T C Veger, Hans van Overhagen, Lukas C van Dijk, Bob Knippenberg
OBJECTIVE/BACKGROUND: Endovascular aneurysm repair (EVAR) may be associated with renal injury and more insight is needed into potential risk factors. The aim was to identify clinical, anatomical, and peri-procedural parameters as potential risk factors for the occurrence of acute kidney injury (AKI) and to evaluate chronic kidney disease (CKD) after EVAR. METHODS: A cohort of 212 consecutive patients who underwent elective EVAR for abdominal aortic aneurysm from January 2009 to October 2016 was included...
December 2017: European Journal of Vascular and Endovascular Surgery
https://www.readbyqxmd.com/read/29067238/lipid-disorders-in-patients-with-renal-failure-role-in-cardiovascular-events-and-progression-of-chronic-kidney-disease
#8
REVIEW
Luca Visconti, Salvatore Benvenga, Antonio Lacquaniti, Valeria Cernaro, Annamaria Bruzzese, Giovanni Conti, Michele Buemi, Domenico Santoro
The spectrum of lipid disorders in chronic kidney disease (CKD) is usually characterized by high triglycerides and reduced high dense lipoprotein (HDL), associated with normal or slightly reduced low dense lipoprotein (LDL)-cholesterol. This dyslipidemia is associated with an increased risk for atherosclerotic cardiovascular disease. Keys for the cardiovascular risk reduction in these patients are lowering the number and modifying the composition of the cholesterol-carrying atherogenic lipoprotein particles...
December 2016: Journal of Clinical & Translational Endocrinology
https://www.readbyqxmd.com/read/29045728/how-do-primary-care-doctors-in-england-and-wales-code-and-manage-people-with-chronic-kidney-disease-results-from-the-national-chronic-kidney-disease-audit
#9
Lois G Kim, Faye Cleary, David C Wheeler, Ben Caplin, Dorothea Nitsch, Sally A Hull
Background: In the UK, primary care records are electronic and require doctors to ascribe disease codes to direct care plans and facilitate safe prescribing. We investigated factors associated with coding of chronic kidney disease (CKD) in patients with reduced kidney function and the impact this has on patient management. Methods: We identified patients meeting biochemical criteria for CKD (two estimated glomerular filtration rates <60 mL/min/1.73 m2 taken >90 days apart) from 1039 general practitioner (GP) practices in a UK audit...
October 16, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/28976899/community-noise-exposure-and-its-effect-on-blood-pressure-and-renal-function-in-patients-with-hypertension-and-cardiovascular-disease
#10
Angel M Dzhambov, Mariya P Tokmakova, Penka D Gatseva, Nikolai G Zdravkov, Dolina G Gencheva, Nevena G Ivanova, Krasimir I Karastanev, Stefka V Vladeva, Aleksandar T Donchev, Svetlan M Dermendzhiev
BACKGROUND: Road traffic noise (RTN) is a risk factor for cardiovascular disease (CVD) and hypertension; however, few studies have looked into its association with blood pressure (BP) and renal function in patients with prior CVD. AIM: This study aimed to explore the effect of residential RTN exposure on BP and renal function in patients with CVD from Plovdiv Province. MATERIALS AND METHODS: We included 217 patients with ischemic heart disease and/or hypertension from three tertiary hospitals in the city of Plovdiv (March - May 2016)...
September 1, 2017: Folia Medica
https://www.readbyqxmd.com/read/28971600/fgf23-level-and-intima-media-thickness-are-elevated-from-early-stages-of-chronic-kidney-disease
#11
Andreja Figurek, Goce Spasovski, Snjezana Popovic-Pejicic
Considering high cardiovascular (CV) risk in chronic kidney disease (CKD), the aim of this cross-sectional study was to assess the association between carotid intima-media thickness (IMT) and fibroblast growth factor (FGF) 23 as important players in CV pathophysiology. Eighty-seven patients with mean estimated glomerular filtration rate 40.1 mL/min per 1.73 m(2) were involved. FGF23 and IMT were elevated from early stages of CKD. Mean IMT value was 1.10 ± 0.20 mm, being significantly elevated starting from early CKD, showing no correlation with FGF23 (r = -0...
October 3, 2017: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/28960806/regional-evidence-and-international-recommendations-to-guide-lipid-management-in-asian-patients-with-type-2-diabetes-with-special-reference-to-renal-dysfunction
#12
REVIEW
Titus Wl Lau, Kevin E K Tan, Jason C J Choo, Tsun-Gun Ng, Subramaniam Tavintharan, Juliana C N Chan
The anticipated increase in the prevalence and incidence of type 2 diabetes in Asia, and its associated cardiovascular-renal complications, will place a significant burden on patients, caregivers, and society. Despite the proven effectiveness of lipid management in reducing these complications, there are major treatment gaps, especially in Asian patients with young-onset diabetes and chronic kidney disease (CKD). Recent international guidelines recommended the adoption of absolute risk estimation of atherosclerosis and cardiovascular disease to guide treatment intensity...
September 28, 2017: Journal of Diabetes
https://www.readbyqxmd.com/read/28935472/treatment-of-superficial-femoral-artery%C3%A2-restenosis
#13
Andrew J Miller, Edwin A Takahashi, William S Harmsen, Kristin C Mara, Sanjay Misra
PURPOSE: To determine the predictors of restenosis, major adverse limb events (MALEs), postoperative death (POD), and all-cause mortality after repeat endovascular treatment of superficial femoral artery (SFA) restenosis. MATERIALS AND METHODS: This was a retrospective review of 440 patients with 518 SFA lesions who were treated between January 2002 and October 2011. Ninety-six limbs were treated for restenosis with bare metal stents (BMSs) or percutaneous transluminal angioplasty (PTA), of which 28 limbs developed another restenosis requiring a third procedure...
December 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28836857/uric-acid-and-incident-chronic-kidney-disease-in-dyslipidemic-individuals
#14
Fotios Barkas, Moses Elisaf, Evangelos Liberopoulos, Rigas Kalaitzidis, George Liamis
BACKGROUND: Elevated uric acid (UA) is a recognized risk factor for chronic kidney disease (CKD). This study aimed to investigate whether this association exists in dyslipidemic patients receiving multifactorial treatment. METHODS: An observational study conducted in Greece including 1,269 dyslipidemic individuals followed-up in a lipid clinic for ≥3 years. Estimated glomerular filtration rate (eGFR) was calculated by CKD-EPI equation and CKD was defined as ≤60 mL/min/1...
September 21, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28835613/residual-risk-factors-to-predict-major-adverse-cardiovascular-events-in-atherosclerotic-cardiovascular-disease-patients-with-and-without-diabetes-mellitus
#15
Fang-Ju Lin, Wei-Kung Tseng, Wei-Hsian Yin, Hung-I Yeh, Jaw-Wen Chen, Chau-Chung Wu
A prospective observational study was conducted to investigate the residual risk factors to predict recurrence of major adverse cardiovascular events (MACE) in atherosclerotic cardiovascular disease (ASCVD) patients with a high prevalence under lipid-lowering therapy, particularly in the subpopulations of diabetic and nondiabetic individuals. A total of 5,483 adults (with a mean age of 66.4 and 73.3% male) with established coronary heart disease, cerebrovascular disease, or peripheral artery disease were identified from the T-SPARCLE multi-center registry...
August 23, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28796030/the-renoprotective-effects-of-simvastatin-and-atorvastatin-in-patients-with-acute-coronary-syndrome-undergoing-percutaneous-coronary-intervention-an-observational-study
#16
Huan Ma, Yong Liu, Haixia Xie, Guolin Zhang, Huimin Zhan, Zhi Liu, Ping Wang, Qingshan Geng, Lan Guo
Some statins, such as atorvastatin, have proven renoprotective effects. The comparative renoprotective potential of simvastatin is less clear. This study aimed to compare the renoprotective effects of simvastatin with atorvastatin in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). This observational study examined the medical records of 271 patients who were treated at the Guangdong Cardiovascular Institute from April 2004 to February 2008. Patients had received either 40 mg simvastatin (n = 128) or 20 mg atorvastatin (n = 143), daily, for a period of at least 6 months following PCI...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28682890/efficacy-of-short-term-moderate-or-high-dose-rosuvastatin-in-preventing-contrast-induced-nephropathy-a-meta-analysis-of-15-randomized-controlled-trials
#17
REVIEW
Min Liang, Shicheng Yang, Naikuan Fu
BACKGROUND: The prophylactic efficacy of statin pretreatment for the prevention of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI) remains controversial. The aim of the study was to perform a meta-analysis of randomized controlled trials (RCTs) to assess the effectiveness of short-term moderate or high-dose rosuvastatin pretreatment in preventing CIN. METHODS: We included RCTs comparing short-term moderate or high-dose rosuvastatin treatment versus low-dose rosuvastatin treatment or placebo for preventing CIN...
July 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28676027/the-co-existence-of-nash-and-chronic-kidney-disease-boosts-cardiovascular-risk-are-there-any-common-therapeutic-options
#18
Marianna Papademetriou, Vasilios G Athyros, Eleni Geladari, Michael Doumas, Costas Tsioufis, Vasilios Papademetriou
Non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease. NAFLD may evolve to non-alcoholic steatohepatitis (NASH), which is causally related to cirrhosis and cardiovascular disease (CVD) mortality. There is no generally accepted effective treatment for NAFLD/NASH. Chronic kidney disease (CKD) is relatively common and might co-exist with NAFLD/NASH, aggravate one another, and increase CVD risk. Common therapies could improve outcome. Potent statins at high doses, such as atorvastatin and rosuvastatin, ameliorate NAFLD/NASH and reduce the mortality rates by half as compared with those on the same statins but without liver disease...
June 20, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28635327/within-visit-blood-pressure-variability-and-cardiovascular-risk-factors-in-hypertensive-patients-with-non-dialysis-chronic-kidney-disease
#19
Kengo Azushima, Hiromichi Wakui, Kazushi Uneda, Sona Haku, Ryu Kobayashi, Kohji Ohki, Sho Kinguchi, Kotaro Haruhara, Tetsuya Fujikawa, Yoshiyuki Toya, Satoshi Umemura, Kouichi Tamura
As there may be an association between within-visit blood pressure (BP) variability and cardiovascular disease (CVD), we investigated the clinical significance of this BP variability in non-dialysis chronic kidney disease (CKD) patients. MATERIALS AND METHODS: According to the median of coefficient of variation (CV) of three systolic BP (SBP) readings within a single visit, we divided hypertensive patients with stage G1-4 CKD already treated with antihypertensive therapy into the high SBP-CV group and the low SBP-CV group...
June 21, 2017: Clinical and Experimental Hypertension: CHE
https://www.readbyqxmd.com/read/28628255/still-a-reasonable-goal-targeting-cholesterol-in-dialysis-and-advanced-chronic-kidney-disease-patients
#20
EDITORIAL
Gunnar H Heine, Kyrill S Rogacev, Oliver Weingärtner, Gunther Marsche
Chronic kidney disease (CKD) patients have a high burden of cardiovascular disease. In the general population, lipid metabolism disorders, which cause the initiation and progression of atherosclerotic vascular changes, are major targets for preventive and therapeutic strategies in cardiovascular medicine. However, data from large cohort studies and from clinical trials suggest that the treatment guidelines on cardiovascular disease prevention and therapy cannot uncritically be transferred from individuals with intact renal function to CKD patients...
September 2017: Seminars in Dialysis
keyword
keyword
24253
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"